Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older

NCT04470427 is registered in ClinicalTrials.gov with ModernaTX, Inc. as lead sponsor.

NCT NCT04470427
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04470427 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older
Lead sponsor
ModernaTX, Inc.
Phase
Phase 3
Overall status
Completed
Start date
July 27, 2020
Completion date
December 29, 2022
Enrollment
30,415 (actual)
Sites
100

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov-2